Ibrutinib Monotherapy for Relapsed or Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Ibrutinib Monotherapy for Relapse or Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma: Final Analysis of the Phase II 'Proof-of-Concept' iLOC Study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network
Eur. J. Cancer 2019 Jul 03;117(xx)121-130, C Soussain, S Choquet, M Blonski, D Leclercq, C Houillier, K Rezai, F Bijou, R Houot, E Boyle, R Gressin, E Nicolas-Virelizier, M Barrie, C Moluçon-Chabrot, ML Lelez, A Clavert, S Coisy, S Leruez, V Touitou, N Cassoux, M Daniau, M Ertault de la Bretonnière, A El Yamani, H Ghesquières, K Hoang-XuanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.